Premium
Serum γ‐enolase and prognosis of patients with renal cell carcinoma
Author(s) -
Rasmuson Torgny,
Grankvist Kjell,
Ljungberg Börje
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19930815)72:4<1324::aid-cncr2820720429>3.0.co;2-w
Subject(s) - enolase , medicine , renal cell carcinoma , immunoradiometric assay , carcinoma , adjuvant therapy , stage (stratigraphy) , proportional hazards model , kidney disease , pathology , oncology , gastroenterology , cancer , radioimmunoassay , immunohistochemistry , biology , paleontology
Background . Increased levels of gamma‐enolase (γ‐enolase) have been observed in the sera of patients with renal cell carcinoma. To evaluate the prognostic information of γ‐enolase in this disease, 161 consecutive patients were assessed before initiation of therapy. Methods . γ‐Enolase was analyzed in serum using an immunoradiometric assay. The patients were clinically staged and followed up for a median time of 36 months (range, 5–104 months). Actuarial survival was calculated using the Kaplan‐Meier method. Results . Elevated levels of γ‐enolase was found in 28 of 61 (46%) patients with distant metastases, compared with 8 of 56 (14%) when the tumor was confined to the kidney. A correlation also was observed between γ‐enolase and tumor grade, with poorly differentiated tumors having the highest levels. In 28 patients with distant metastases and elevated γ‐enolase, the survival time was significantly shorter than that of 31 patients with normal γ‐enolase levels (P < 0.001). The median survival time was 5 and 11 months, respectively. Using Cox proportional hazard model, clinical stage, serum γ‐enolase, and tumor grade were identified as independent prognostic factors. Conclusion . Serum γ‐enolase can be useful as an adjunct in the staging of renal cell carcinoma. It also gives predictive information and might be of value as a marker in adjuvant therapy. Cancer 1993; 72:1324‐8.